Anti-Aging Peptides
Explore longevity-related peptide research by evidence type: cell and animal experiments, human biomarkers, topical studies and specific approved-product uses.
Category Overview
Research in this category examines telomere biology, mitochondrial function, senescent cells, immune changes and tissue repair. A cellular or animal endpoint can be a promising research signal without demonstrating longer human lifespan or reversal of aging.
GHK-Cu has formulation-specific topical human findings as well as cell and animal research. Those findings do not establish injectable rejuvenation. FOXO4-DRI remains cell/mouse treatment research, while humanin comparisons in people concern biomarkers rather than administered-human efficacy.
Product and outcome matter: FDA granted Forzinity accelerated approval for muscle strength in Barth syndrome at a body weight of at least 30 kg. This is a specific disease/product indication, not an anti-aging indication or approval of every SS-31 product. Humanin/HNG animal findings include metabolic benefits without significant female-mouse lifespan extension.
All Anti-Aging Peptides
Formulation-specific topical human results, including a small eyebrow study, do not establish injectable efficacy. A compounding-category entry does not establish FDA approval of an injectable product.
Small retinal and circadian-biomarker reports do not demonstrate longer human lifespan or clinical insomnia relief. FDA’s 2026 assessment distinguishes free base and acetate and states neither is an approved-drug component; compounding policy is separate.
Human sepsis findings are mixed; corrected estimates do not establish broad immune benefits.
Academic cell and mouse research reports selected tissue-function and frailty-related benefits. These findings do not demonstrate human aging reversal or establish a human nasal or subcutaneous regimen.
Limited human reports and a rectal-trial account do not establish a general treatment effect. FDA states the assessed free-base and acetate forms are not components of approved drugs; pending policy review is separate.
Forzinity has a specific accelerated-approval muscle-strength indication in Barth syndrome at 30 kg or greater. This does not establish general anti-aging benefit or approval of every SS-31 product.
Native-peptide administration findings remain preclinical in the assessed evidence; endogenous human observations, a recruiting registry and modified-analog findings are separate. FDA states assessed forms are not approved-drug components.
Cell and animal treatment findings are distinct from human biomarker comparisons. HNG improved selected metabolic measures without significantly extending female mouse lifespan. These sources do not establish a human treatment regimen.
Disclaimer: Anti-aging peptides are largely in the research stage. No peptide has been FDA-approved as an anti-aging treatment. This information is for educational purposes only. Consult a healthcare provider before using any peptide therapy.